Table : List of resources to be considered in the economic analysis Number of Disaggregated unit cost units of Proportion of resource per Provider of Setting in which patients relevant time Other Private Safety resource resource is provided receiving horizon per MBS government health Patient Total cost nets* resource patient budget insurer receiving resource Resources provided to identify eligible population Equivalent to current To be provided To be provided in in practice submission submission Resources provided to deliver proposed intervention (PD-L1 IHC test and pembrolizumab) To be provided To be provided PD-L1 IHC testing MBS Pathology lab in in submission submission Additional lung biopsy MBS Public or private To be provided To be provided in in (depending on place in hospital submission submission therapy of test) Resources provided in association with proposed intervention To be provided To be provided Pembrolizumab for patients PBS Outpatient in in deemed eligible based on submission submission PBS criteria Administration cost for Hospitals/MBS Blend of To be provided To be provided in in pembrolizumab inpatient/outpatient submission submission and public and private hospitals To be provided To be provided Physician visits (Oncologist MBS Outpatient in in or respiratory physician) submission submission Clinical monitoring MBS Outpatient To be provided To be provided in in (radiological or other submission submission imaging, blood counts) To be provided To be provided Treatment of adverse PBS Outpatient in in events submission submission
Table : List of resources to be considered in the economic analysis Provider of resource Setting in which resource is provided Proportion of patients receiving resource Number of units of resource per relevant time horizon per patient receiving resource Disaggregated unit cost MBS Safety nets* Other government budget Private health insurer Patient Total cost Resources provided to identify eligible population Equivalent to current practice To be provided in submission To be provided in submission Resources provided to deliver proposed intervention (PD-L1 IHC test and pembrolizumab) PD-L1 IHC testing MBS Pathology lab To be provided in submission To be provided in submission Additional lung biopsy (depending on place in therapy of test) MBS Public or private hospital To be provided in submission To be provided in submission Resources provided in association with proposed intervention Pembrolizumab for patients deemed eligible based on PBS criteria PBS Outpatient To be provided in submission To be provided in submission Administration cost for pembrolizumab Hospitals/MBS Blend of inpatient/outpatient and public and private hospitals To be provided in submission To be provided in submission Physician visits (Oncologist or respiratory physician) MBS Outpatient To be provided in submission To be provided in submission Clinical monitoring (radiological or other imaging, blood counts) MBS Outpatient To be provided in submission To be provided in submission Treatment of adverse events PBS Outpatient To be provided in submission To be provided in submission
1414-FinalProtocol-REDACTIONS-accessible.docx